DRI Healthcare

DRI Healthcare would like to welcome Elaine Tee to the team as VP, Finance.

Our CEO, Ali Hedayat, joined BNN's Trading Day to discuss our recent acquisition after reporting quarterly earnings. Watch here: https://lnkd.in/g4XKaxwx

Yesterday, we announced the acquisition of a synthetic royalty interest in the worldwide sales of sebestralstat for the treatment of hereditary angioedema (“HAE”) plus a private placement in KalVista Pharmaceuticals, Inc. for a total investment of up to US$184 million. If approved, sebetralstat would be the first and only oral on-demand therapy for treating attacks associated with HAE. This is the Trust’s first pre-approval royalty acquisition and first equity investment, highlight our evolving investment strategy. Read more: https://lnkd.in/gpWY7gg9

DRI Healthcare is looking for a Legal Associate to join our team! We are looking for a self-motivated and proactive attorney with corporate and transactional experience. If you or anyone you know is interested in applying, please feel free to reach out or click the link below. https://lnkd.in/gnQhey6Y

Today, we announced the acquisition of a portion of Editas Medicine, Inc.’s payment rights under a non-exclusive license to Vertex Pharmaceuticals Inc. of Editas Medicine’s Cas9 gene-editing technology for CASGEVY® (exagamglogene autotemcel) for an upfront purchase price of US$57 million. This transaction adds another innovative rare disease therapy to our portfolio, and the novel deal structure offers predictable annual cash flows as well as potential additional annual sales-based milestones and a one-time contingent payment. Read more: https://lnkd.in/g-DmcfSk

DRI is looking for a highly motivated and results-driven individual to join our Finance team as a Vice President, Finance. The Vice President, Finance will primarily be responsible for the corporate accounting, reporting, controls and systems related to DRI Capital Inc. If you or anyone you know is interested in applying, please feel free to reach out or click the link below. https://lnkd.in/gnQhey6Y

Today, we announced that DRI Healthcare has agreed to acquire an additional royalty interest in the worldwide sales of Xenpozyme (olipudase alfa) from HLS Therapeutics Inc. for up to US$45.75 million. Xenpozyme is the only product developed and approved for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency, also known as Niemann-Pick disease, in pediatric and adult patients. We made our first investment in Xenpozyme in November 2022. Xenpozyme has seen strong sales since it was approved in 2022 and we are excited to increase our exposure to this important treatment. Read more: https://lnkd.in/gJt-J62r

DRI Healthcare would like to welcome Ranee Borgna to the team as Executive Assistant & Office Coordinator.

DRI Healthcare would like to welcome David Jimenez to the team as Analyst, Asset Operations & Analytics.

DRI Healthcare would like to welcome Yang (Serena) Li to the team as Legal Counsel.